Cover Image
市場調查報告書

社區型肺炎(CAP):全球臨床實驗檢討

Community Acquired Pneumonia Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 320348
出版日期 內容資訊 英文 207 Pages
訂單完成後即時交付
價格
Back to Top
社區型肺炎(CAP):全球臨床實驗檢討 Community Acquired Pneumonia Global Clinical Trials Review, H1, 2017
出版日期: 2017年06月30日 內容資訊: 英文 207 Pages
簡介

社區型肺炎(CAP)是臨床醫生臨診中最常見的傳染病之一。CAP是全球死亡率與罹患率的重要原因。許多病原體都可能引發CAP。引起症狀的代表性細菌性病原體為肺炎球菌(penicillin敏感性、penicillin抗藥性)、流行性感冒嗜血桿菌(Ampicillin敏感性、Ampicillin抗藥性)、卡他莫拉菌(moraxella catarrhalis,MC)(全都是penicillin抗藥性)。這三種病原體約佔CAP病例的85%。CAP一般由肺部一區或肺葉吸入肺的病原菌細菌造成感染。雖然不常見,但也有可能引發大腸菌的泌尿道感染或菌血症、二次菌血症等併發症。誤嚥性肺炎是由複數的病原體(例如好氧/厭氧口腔內微生物)引發的唯一型態。

本報告提供社區型肺炎(CAP)的治療藥相關之臨床實驗調查分析,提供您臨床實驗數及受驗人數,各階段及Phase狀況,有潛力的企業,正在開發的治療藥資訊,臨床實驗簡介等相關的系統性資訊。

目錄

簡介

各地區的臨床實驗

  • 各國臨床實驗趨勢
    • 亞太地區的主要國家
    • 歐洲的主要國家
    • 北美的主要國家
    • 中東·非洲的主要國家
    • 中南美的主要國家

G7各國的臨床實驗:感染性疾病臨床實驗上社區型肺炎(CAP)所佔的比例

G7各國的臨床實驗:Phase別

G7各國的臨床實驗:各階段

E7各國的臨床實驗:感染性疾病臨床實驗上社區型肺炎(CAP)所佔的比例

E7各國的臨床實驗:Phase別

E7各國的臨床實驗:各階段

Phase別臨床實驗

各階段臨床實驗

評估項目別臨床實驗

未完成的臨床實驗

一定期間所採用的實驗對象

贊助商類別臨床實驗

有潛力的贊助商

  • 社區型肺炎(CAP)的治療藥臨床實驗之主要參與企業

有潛力藥物

臨床實驗簡介

  • 主要企業臨床實驗概要
    • Pfizer Inc.
    • TaiGen Biopharmaceuticals Holdings Limited
    • Sanofi
    • Actavis plc
    • Bayer AG
    • Melinta Therapeutics, Inc
    • Novartis AG
    • GlaxoSmithKline plc
    • AstraZeneca PLC
    • Abbott Laboratories
  • 主要大學·研究機關·醫院臨床實驗概要
    • St. Antonius Hospital
    • University Hospital Basel
    • University of Milan
    • HaEmek Medical Center
    • Medical Center Alkmaar
    • Spanish National Health System
    • Carlos III Health Institute
    • Nagasaki Evaluation Organization for Clinical Interventions
    • 小野市立小野市民醫院
    • University of Roma La Sapienza

主要的臨床簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4322CTIDB

GlobalData's clinical trial report, "Community Acquired Pneumonia Global Clinical Trials Review, H1, 2017" provides an overview of Community Acquired Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Community Acquired Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 22
  • Clinical Trials in E7 Countries by Trial Status 23
  • Clinical Trials by Phase 24
  • In Progress Trials by Phase 25
  • Clinical Trials by Trial Status 26
  • Clinical Trials by End Point Status 28
  • Subjects Recruited Over a Period of Time 29
  • Clinical Trials by Sponsor Type 30
  • Prominent Sponsors 31
  • Top Companies Participating in Community Acquired Pneumonia Therapeutics Clinical Trials 33
  • Prominent Drugs 35
  • Latest Clinical Trials News on Community Acquired Pneumonia 36
  • May 30, 2017: TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn Intravenous Formulation to the China Food and Drug Administration 36
  • Clinical Trial Profile Snapshots 37

Appendix 204

  • Abbreviations 204
  • Definitions 204
  • Research Methodology 205
  • Secondary Research 205
  • About GlobalData 206
  • Contact Us 206
  • Source 206

List of Tables

List of Tables

  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Community Acquired Pneumonia Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
  • Community Acquired Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Community Acquired Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 22
  • Community Acquired Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Community Acquired Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Phase, 2017* 25
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
  • Community Acquired Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 31
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36

List of Figures

List of Figures

  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Community Acquired Pneumonia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
  • Community Acquired Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Community Acquired Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Community Acquired Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 21
  • Community Acquired Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
  • Community Acquired Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26
  • Community Acquired Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
  • Community Acquired Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 31
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
  • Community Acquired Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36
  • GlobalData Methodology 206
Back to Top